The authors thank Stephanie Duret for coordinating the clinical visits of the ESCS patients who participated in this study.
Supported by a grant from the National Eye Institute Bioengineering Partnership (R01EY023591), by an American Academy of Optometry Foundation Ezell Fellowship, by the Hellman Fellows Fund, by an Alcon Research Institute Young Investigator Award, by Foundation Fighting Blindness, by the UCSF Vision Core shared resource of a National Eye Institute Center Core Grant for Vision Research (P30 EY002162), and by an unrestricted grant from Research to Prevent Blindness.
Disclosure: Y. Wang, None; J. Wong, None; J.L. Duncan, Acucela (F), Allergan/Abbvie (F), Second Sight Medical Products (F), Biogen/Nightstarx Therapeutics (F), Neurotech USA (F), AGTC (C), DTx Therapeutics (C), Editas (C), Eyevensys (C), Gyroscope (C), Helios (C), Nacuity (C), Spark Therapeutics (C), SparingVision (C), ProQR Therapeutics (C), PYC Therapeutics (C), Vedere Bio (C), RxSight (I); A. Roorda, C. Light Technologies (I), University of Rochester (P), University of Houston (P); W.S. Tuten, Quadrant Eye (C)